Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx for Testicular Injury and Oligospermia
NCT05158114Phase 1Withdrawn
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in testicular injury and oligospermia, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Safety (adverse events) at 4 years. Planned start Apr 2025; status: withdrawn.
02
Drugs
AlloRx
03
Conditions
testicular injuryoligospermia
Beyond the preview
Go deeper on NCT05158114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158114.